[HTML][HTML] 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - ncbi.nlm.nih.gov
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …

N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations

LC Tao, J Xu, T Wang, F Hua, JJ Li - Cardiovascular diabetology, 2022 - Springer
The triglyceride-glucose (TyG) index has been identified as a reliable alternative biomarker
of insulin resistance (IR). Recently, a considerable number of studies have provided robust …

3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials

Y Shi, H Zhang, S Huang, L Yin, F Wang… - … and Targeted Therapy, 2022 - nature.com
Epigenetics is closely related to cardiovascular diseases. Genome-wide linkage and
association analyses and candidate gene approaches illustrate the multigenic complexity of …

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …

F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models

RG Lee, AM Mazzola, MC Braun, C Platt, SB Vafai… - Circulation, 2023 - Am Heart Assoc
Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …

F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Cardiovascular disease in diabetes, beyond glucose

RH Eckel, KE Bornfeldt, IJ Goldberg - Cell metabolism, 2021 - cell.com
Despite the decades-old knowledge that diabetes mellitus is a major risk factor for
cardiovascular disease, the reasons for this association are only partially understood. While …